Polyglutamine diseases are a class of neurodegenerative diseases associated with the accumulation of aggregated mutant proteins. We previously developed a class of degradation-inducing agents targeting the β-sheet-rich structure typical of such aggregates, and we showed that these agents dose-, time-, and proteasome-dependently decrease the intracellular level of mutant huntingtin with an extended polyglutamine tract, which correlates well with the severity of Huntington's disease. Here, we demonstrate that the same agents also deplete other polyglutamine disease-related proteins: mutant ataxin-3 and ataxin-7 in cells from spino-cerebellar ataxia patients, and mutant atrophin-1 in cells from dentatorubral-pallidoluysian atrophy patients. Targeting cross-β-sheet structure could be an effective design strategy to develop therapeutic agents for multiple neurodegenerative diseases.
Keywords: Polyglutamine diseases; Protein knockdown.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Targeting several CAG expansion diseases by a single antisense oligonucleotide.PLoS One. 2011;6(9):e24308. doi: 10.1371/journal.pone.0024308. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21909428 Free PMC article.
Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression.Mol Ther Nucleic Acids. 2020 Mar 6;19:562-571. doi: 10.1016/j.omtn.2019.12.012. Epub 2019 Dec 18. Mol Ther Nucleic Acids. 2020. PMID: 31927329 Free PMC article.
T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.Neuropharmacology. 2015 Dec;99:308-17. doi: 10.1016/j.neuropharm.2015.08.009. Epub 2015 Aug 6. Neuropharmacology. 2015. PMID: 26254860
Potential therapeutic targets in polyglutamine-mediated diseases.Expert Rev Neurother. 2014 Oct;14(10):1215-28. doi: 10.1586/14737175.2014.956727. Epub 2014 Sep 4. Expert Rev Neurother. 2014. PMID: 25190502 Review.
Studying polyglutamine diseases in Drosophila.Exp Neurol. 2015 Dec;274(Pt A):25-41. doi: 10.1016/j.expneurol.2015.08.002. Epub 2015 Aug 6. Exp Neurol. 2015. PMID: 26257024 Free PMC article. Review.